News | April 30, 2015

PET agent provides higher-quality images from first generation at half the dose

prostate cancer, [18F]DCFPyL, PSMA, biomarker, Johns Hopkins, WMIS

April 30, 2015 — A first-in-human prostate cancer study in the Journal of Molecular Imaging and Biology showed initial safety, biodistribution and dosimetry results with [18F]DCFPyL, a second-generation fluorine-18 labeled small-molecule prostate-specific membrane antigen (PSMA) inhibitor. The imaging biomarker has been developed at Johns Hopkins University in Baltimore by study co-author Martin G. Pomper, M.D., Ph.D.

“This initial human evaluation of [18F]DCFPyL demonstrated a number of important findings. The radiotracer was safe, and parallels the expected uptake with significantly improved visual conspicuity of suspected sites of metastatic prostate cancer in comparison to our first generation radiotracer,” said Pomper, William R. Brody Professor of Radiology at Johns Hopkins.

[18F]DCFPyL is a second-generation small-molecule positron emission tomography (PET) agent that attaches to the PSMA. Signals from [18F]DCFPyL can then be measured via a PET scan. The study demonstrated that [18F]DCFPyL produced images that showed lower blood pool activity, providing clearer images than the first-generation agent, [18F]DCFBC, produced by the same group. The study also showed 50 percent lower radiation dose in the most sensitive organs.

According to the American Cancer Society, about 220,800 new cases and 27,540 deaths will occur from prostate cancer in the United States in 2015. While prostate cancer is often curable, there remain a large number of patients with residual, recurrent and metastatic disease who need imaging for lesion detection, therapeutic monitoring and restaging. Conventional imaging has not proven to be sufficiently sensitive and specific for detection of prostate cancer lesions.

“The basis of more accurate, molecularly-informed classification of disease is the premise of precision medicine and specific molecular imaging biomarkers are the keys to determine how we classify diseases, how we select therapy, how we monitor therapy, and ultimately how we make treatments more accurate for each individual for better patient outcomes,” said Jason Lewis, M.D,. Ph.D., professor and vice chair for research, Emily Tow Jackson Chair at Memorial Sloan-Kettering Cancer Center, and president of the World Molecular Imaging Society (WMIS). “We commend the team at Johns Hopkins for developing a more sensitive and accurate PSMA.”

For more information: www.wmis.org


Related Content

News | Prostate Cancer

July 30, 2024 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 25, 2024 — NorthStar Medical Radioisotopes, LLC and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc ...

Time July 25, 2024
arrow
News | PET-CT

July 25, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET & PET-CT imaging ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | ASTRO

June 21, 2024 — The American Society for Radiation Oncology (ASTRO) announced today that following a nationwide search ...

Time June 21, 2024
arrow
News | Artificial Intelligence

June 17, 2024 — Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care ...

Time June 17, 2024
arrow
News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | PET Imaging

June 14, 2024 — Positron Corporation, a leading molecular imaging medical device company offering PET and PET-CT ...

Time June 14, 2024
arrow
News | SNMMI

June 13, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted more than 8,000 physicians ...

Time June 13, 2024
arrow
Subscribe Now